Remdesivir for COVID-19: Why Not Dose Higher?
作者信息
Yan Victoria C, Muller Florian L
机构信息
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02713-20.
Abstract
摘要
相似文献
1
Remdesivir for COVID-19: Why Not Dose Higher?瑞德西韦用于治疗新冠肺炎：为何不加大剂量？
Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.02713-20.
2
Clinical pharmacodynamics of obeldesivir versus remdesivir.奥贝德西韦与瑞德西韦的临床药效学
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0096924. doi: 10.1128/aac.00969-24. Epub 2024 Aug 12.
3
Broad-Spectrum Antiviral Activity of ODBG-P-RVn: An Orally-Available, Lipid-Modified Monophosphate Prodrug of Remdesivir Parent Nucleoside (GS-441524).ODBG-P-RVn 广谱抗病毒活性：一种口服可利用的、脂修饰的瑞德西韦前药单磷酸酯（GS-441524）。
Microbiol Spectr. 2021 Dec 22;9(3):e0153721. doi: 10.1128/Spectrum.01537-21. Epub 2021 Nov 24.
4
COVID-19 updates: Remdesivir (Veklury) in high-risk outpatients with COVID-19.2019冠状病毒病最新情况：瑞德西韦（Veklury）用于高危2019冠状病毒病门诊患者。
Med Lett Drugs Ther. 2022 Feb 21;64(1644):31-32.
5
Remdesivir as a broad-spectrum antiviral drug against COVID-19.瑞德西韦作为一种广谱抗 COVID-19 病毒药物。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):541-548. doi: 10.26355/eurrev_202101_24426.
6
Update Alert 2: Remdesivir for Adults With COVID-19.最新警报2：用于成人新冠肺炎患者的瑞德西韦。
Ann Intern Med. 2021 Dec;174(12):W114-W115. doi: 10.7326/L21-0600. Epub 2021 Oct 5.
7
Remdesivir for patients with COVID-19.瑞德西韦用于治疗新冠肺炎患者。
CMAJ. 2021 Jan 25;193(4):E125. doi: 10.1503/cmaj.202505. Epub 2021 Jan 6.
8
Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.瑞德西韦的药代动力学及其药物相互作用模拟
J Pharm Pharm Sci. 2021;24:277-291. doi: 10.18433/jpps32011.
9
Remdesivir: a pendulum in a pandemic.瑞德西韦：大流行中的钟摆。
BMJ. 2020 Nov 24;371:m4560. doi: 10.1136/bmj.m4560.
10
Efficacy of Remdesivir for COVID-19.瑞德西韦治疗 COVID-19 的疗效。
Discov Med. 2021 Mar-Apr;31(163):57-60.
引用本文的文献
1
Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19.瑞德西韦及其代谢物GS-441524在COVID-19住院患者中的群体药代动力学建模
Clin Pharmacokinet. 2025 May;64(5):743-756. doi: 10.1007/s40262-025-01496-2. Epub 2025 Apr 22.
2
Development of Targeted Drug Delivery System for the Treatment of SARS-CoV-2 Using Aptamer-Conjugated Gold Nanoparticles.使用适配体偶联金纳米颗粒开发用于治疗新型冠状病毒肺炎的靶向给药系统。
Pharmaceutics. 2024 Sep 30;16(10):1288. doi: 10.3390/pharmaceutics16101288.
3
Clinical pharmacodynamics of obeldesivir versus remdesivir.奥贝德西韦与瑞德西韦的临床药效学
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0096924. doi: 10.1128/aac.00969-24. Epub 2024 Aug 12.
4
Remdesivir treatment does not reduce viral titers in patients with COVID-19.瑞德西韦治疗不能降低 COVID-19 患者的病毒滴度。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0085624. doi: 10.1128/aac.00856-24. Epub 2024 Jul 18.
5
Remdesivir: Quo vadis?瑞德西韦：路在何方？
Biochem Pharmacol. 2021 Nov;193:114800. doi: 10.1016/j.bcp.2021.114800. Epub 2021 Oct 19.
6
Injectable niclosamide nanohybrid as an anti-SARS-CoV-2 strategy.可注射的尼氯硝唑纳米杂化体作为一种抗 SARS-CoV-2 的策略。
Colloids Surf B Biointerfaces. 2021 Dec;208:112063. doi: 10.1016/j.colsurfb.2021.112063. Epub 2021 Aug 24.
7
Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver.单细胞RNA测序支持瑞德西韦在肝脏中的优先生物活化。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0133321. doi: 10.1128/AAC.01333-21.
8
Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola.瑞德西韦为何失败：临床前假设高估了瑞德西韦对新冠病毒和埃博拉病毒的临床疗效。
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0111721. doi: 10.1128/AAC.01117-21. Epub 2021 Jul 12.
本文引用的文献
1
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.瑞德西韦代谢产物 GS-441524 有效抑制 SARS-CoV-2 感染的小鼠模型。
J Med Chem. 2022 Feb 24;65(4):2785-2793. doi: 10.1021/acs.jmedchem.0c01929. Epub 2021 Feb 1.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Off-Target Profiling Demonstrates that Remdesivir Is a Highly Selective Antiviral Agent.脱靶分析表明瑞德西韦是一种高度选择性的抗病毒药物。
Antimicrob Agents Chemother. 2021 Jan 20;65(2). doi: 10.1128/AAC.02237-20.
4
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.瑞德西韦对比标准治疗对 11 天内中症 COVID-19 患者临床状态的影响：一项随机临床试验。
JAMA. 2020 Sep 15;324(11):1048-1057. doi: 10.1001/jama.2020.16349.
5
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.用于治疗新冠病毒病时，母体核苷GS-441524相对于瑞德西韦的优势。
ACS Med Chem Lett. 2020 Jun 23;11(7):1361-1366. doi: 10.1021/acsmedchemlett.0c00316. eCollection 2020 Jul 9.
6
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.瑞德西韦治疗 COVID-19 的安全性、耐受性和药代动力学：一项在健康受试者中的研究。
Clin Transl Sci. 2020 Sep;13(5):896-906. doi: 10.1111/cts.12840. Epub 2020 Aug 5.
7
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.瑞德西韦治疗重症 COVID-19 患者的 5 天与 10 天疗程比较
N Engl J Med. 2020 Nov 5;383(19):1827-1837. doi: 10.1056/NEJMoa2015301. Epub 2020 May 27.
8
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
9
Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis.使用腺嘌呤核苷类似物 GS-441524 对临床诊断为神经型猫传染性腹膜炎的猫进行抗病毒治疗。
J Vet Intern Med. 2020 Jul;34(4):1587-1593. doi: 10.1111/jvim.15780. Epub 2020 May 22.
10
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.瑞德西韦治疗成人重症 COVID-19 的随机、双盲、安慰剂对照、多中心临床试验。
Lancet. 2020 May 16;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Epub 2020 Apr 29.
Zotero 插件